What's Happening?
Broken String Biosciences has announced new leadership to drive the commercialization of its INDUCE-seq® platform, which maps DNA double-strand breaks to measure on- and off-target editing events in gene
editing therapeutics. Terry Pizzie has been appointed as CEO, bringing extensive experience from leading global life science businesses. The platform provides a faster and more reliable way to quantify gene editing events, crucial for evaluating the impact of gene editing therapies.
Why It's Important?
The commercialization of the INDUCE-seq® platform is significant for advancing gene editing safety and efficacy. By providing precise mapping of DNA breaks, the platform ensures the development of safer and more effective gene editing therapies. This is crucial for the growing field of cell and gene therapy, where accurate assessment of genetic edits is essential for therapeutic success.
What's Next?
Under the new leadership, Broken String Biosciences aims to make INDUCE-seq® the gold standard for gene editing off-target assessment. The company plans to expand access to the platform globally, supporting therapy developers in designing more precise and safer treatments. This expansion is expected to accelerate the development of life-saving therapies.
